title: Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease.
abstract: This study investigated the efficacy and safety of quetiapine versus clozapine in parkinsonian patients with dopaminergic psychosis. All patients fulfilling the inclusion criteria were randomly assigned to receive either quetiapine or clozapine. The duration of the trial was 12 weeks. The severity of psychosis was assessed using the BPRS and the Clinical Global Impression Scale-Severity subscale (CGI-S). The UPDRS III was used to monitor the progression of PD during the study period. Twenty patients, 10 on clozapine, and 10 on quetiapine, completed the study. The psychopathological state, as assessed by the BPRS and by the CGI-S, improved significantly ( p<0.001) from baseline in both treatment groups. No differences were found between clozapine and quetiapine at each assessment time. The UPDRS score decreased significantly ( p<0.05) in the clozapine group, while was almost unchanged in the quetiapine group.
authors.affiliation: Department of Neuroscience, University of Messina, Policlinico Universitario, Via Consolare Valeria, I-98125 Messina, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Morgante
authors.forename: A
authors.initials: A
authors.lastname: Epifanio
authors.forename: E
authors.initials: E
authors.lastname: Spina
authors.forename: A E
authors.initials: AE
authors.lastname: Di Rosa
authors.forename: M
authors.initials: M
authors.lastname: Zappia
authors.forename: G
authors.initials: G
authors.lastname: Basile
authors.forename: P
authors.initials: P
authors.lastname: La Spina
authors.forename: A
authors.initials: A
authors.lastname: Quattrone
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014150:Antipsychotic Agents / Q000494:pharmacology*; D003024:Clozapine / Q000494:pharmacology*; D003987:Dibenzothiazepines / Q000494:pharmacology*; D018450:Disease Progression; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000188:drug therapy*; D000069348:Quetiapine Fumarate
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D018491:Dopamine Agonists; D000069348:Quetiapine Fumarate; D003024:Clozapine